Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics

Lipton, A., Fizazi, K., Stopeck, A.T. et al. (12 more authors) (2016) Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. EUROPEAN JOURNAL OF CANCER, 53. pp. 75-83. ISSN 0959-8049

Abstract

Metadata

Authors/Creators:
  • Lipton, A.
  • Fizazi, K.
  • Stopeck, A.T.
  • Henry, D.H.
  • Smith, M.R.
  • Shore, N.
  • Martin, M.
  • Vadhan-Raj, S.
  • Brown, J.E.
  • Richardson, G.E.
  • Saad, F.
  • Yardley, D.A.
  • Zhou, K.
  • Balakumaran, A.
  • Braun, A.
Copyright, Publisher and Additional Information: © 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Denosumab; Zoledronic acid; Bone metastases; Skeletal-related event; Subgroup
Dates:
  • Published: January 2016
  • Accepted: 16 September 2015
  • Published (online): 13 December 2015
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine (Sheffield) > Division of Genomic Medicine (Sheffield) > Department of Oncology (Sheffield)
The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 07 Jul 2016 15:56
Last Modified: 07 Jul 2016 15:57
Published Version: http://dx.doi.org/10.1016/j.ejca.2015.09.011
Status: Published
Publisher: Elsevier
Refereed: Yes
Identification Number: https://doi.org/10.1016/j.ejca.2015.09.011
Related URLs:

Share / Export

Statistics